Ldn193189

• Catalog Number: ACM1062368244
• Product Name: Ldn193189
• CAS: 1062368-24-4
• Category: Main Products
• Synonyms: S2618_Selleck; cc-233; UNII-W69H5YQU9O; 4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline hydrochloride DM-3189
• IUPAC Name: 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
• Molecular Weight: 406.48
• Molecular Formula: C₂₅H₂₂N₆
• Canonical SMILES: C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3
• InChI Key: CDOVNWNANFFLFJ-UHFFFAOYSA-N
• Appearance: solid
• Exact Mass: 406.19100

Case Study

Effect of LDN193189 on Bone Marrow Stromal Cells

Franco R A G, et al. Stem Cell Reports, 2022, 17(3), 616-632.

LDN193189 is a bone morphogenetic protein (BMP) inhibitor. The effect of the BMP signaling inhibitor LDN 193189 on bone marrow stromal cell (BMSC) differentiation was evaluated in chondrogenic, osteogenic, and adipogenic cultures using assays summarized schematically in the figure. Experimental steps related to LDN 193189 include BMSC microtissue chondrogenic induction cultures, BMSC osteogenic induction cultures, and BMSC adipogenic induction cultures.
Overview of the impact of LDN193189 on BMSC
· Using 14-day microtissue chondrogenesis-inducing cultures, LDN 193189 was found to allow BMSC chondrogenesis but not prevent hypertrophy.
· LDN 193189 was effective enough to antagonize exogenous BMP-2 mineralization and adipogenesis in osteogenic induction cultures.
· LDN 193189 does not alter BMSC behavior in adipogenic cultures.
· Although LDN 193189 was able to effectively antagonize BMP signaling in a manner that affected BMSC fate, this blockade was not sufficient to prevent hypertrophy.